Holen Sie sich die Stockscreener-App
7.27
0.27%
-0.02
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt GRFS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$7.29
Offen:
$7.21
24-Stunden-Volumen:
523.31K
Relative Volume:
0.76
Marktkapitalisierung:
$4.95B
Einnahmen:
$8.62B
Nettoeinkommen (Verlust:
$573.80M
KGV:
10.28
EPS:
0.707
Netto-Cashflow:
$680.05M
1W Leistung:
+1.54%
1M Leistung:
-0.68%
6M Leistung:
-22.41%
1J Leistung:
-25.44%
1-Tages-Spanne:
$7.13
$7.27
1-Wochen-Bereich:
$7.05
$7.315
52-Wochen-Spanne:
$6.96
$11.14
Grifols Sa Adr Stock (GRFS) Company Profile
Compare GRFS vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
7.27 | 4.95B | 8.62B | 573.80M | 680.05M | 0.707 |
LLY
Lilly Eli Co
|
1,188.58 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 618.61B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 438.31B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 305.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 293.94B | 54.66B | 13.58B | 16.05B | 7.0171 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-12 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-03-12 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-04-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2023-01-18 | Hochstufung | Jefferies | Hold → Buy |
| 2022-04-08 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-10-19 | Herabstufung | Barclays | Overweight → Underweight |
| 2021-10-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-06-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Hold |
| 2021-03-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | Hochstufung | HSBC Securities | Hold → Buy |
| 2020-10-01 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-06-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-06-09 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-03-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-06-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-02-08 | Herabstufung | Berenberg | Buy → Hold |
| 2018-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2018-06-01 | Eingeleitet | Barclays | Overweight |
| 2017-10-31 | Eingeleitet | Citigroup | Buy |
| 2017-06-30 | Herabstufung | Goldman | Buy → Neutral |
| 2017-04-06 | Eingeleitet | BofA/Merrill | Buy |
| 2017-01-03 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-02-09 | Hochstufung | Berenberg | Hold → Buy |
| 2016-01-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | Herabstufung | HSBC Securities | Buy → Hold |
| 2015-11-20 | Herabstufung | Berenberg | Buy → Hold |
| 2015-04-28 | Herabstufung | Berenberg | Buy → Hold |
Alle ansehen
Grifols Sa Adr Aktie (GRFS) Neueste Nachrichten
ETFs Investing in Grifols, S.A. Sponsored ADR Class B Stocks - TradingView
G0FB Forecast — Price Target — Prediction for 2027 - TradingView
GRFSGrifols SA ADR Options - Finviz
G0F Forecast — Price Target — Prediction for 2027 - TradingView
Grifols operations profile, Sunday focus on plasma and strategy - AD HOC NEWS
A1C3HH Forecast — Price Target — Prediction for 2027 - TradingView
A1J1E2 Forecast — Price Target — Prediction for 2027 - TradingView
Grifols, S.A. Sponsored ADR Class B Actuals & Estimates (NASDAQ:GRFS) - TradingView
Grifols holds technical support, shares trade in a tight Nasdaq range - AD HOC NEWS
Grifols SA (GRFS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Grifols S.A. Stock (ES0171996087): IBEX 35 plasma specialist in focus after modest gain - Ad-hoc-news.de
GRIFOLS SA-ADR (GRFS) Stock Chart - ChartMill
Grifols Shares Edge Lower as Stock Tests Key Support ZoneVolatility Smirk - newsline.com
Grifols ADR (GRFS) Gains 1.47% as Shares Hold Above Key Support LevelSector Leader Stocks - newsline.com
Grifols S.A. stock (ES0171996087): Q1 2026 figures and rising short interest keep focus on Spanish p - AD HOC NEWS
Grifols S.A. stock (ES0171996087): Spain plasma specialist in focus after volatile trading week - AD HOC NEWS
GRFS Stock Price, Quote & Chart | GRIFOLS SA-ADR (NASDAQ:GRFS) - ChartMill
Grifols S.A. stock (ES0171996087): Debt reduction deal, Q1 update and what matters for US investors - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist regains momentum after earnings update - AD HOC NEWS
Grifols S.A. stock (ES0171996087): plasma specialist back in focus after debt and governance reset - AD HOC NEWS
Grifols SA stock (ES0171996087): AGM plans and Moody’s outlook shift put debt and governance back - AD HOC NEWS
Grifols SA stock (ES0171996087): shareholders eye 2026 AGM after Moody’s outlook boost - AD HOC NEWS
Brandes reports 24.31% stake in Grifols (NASDAQ: GRFS) in Schedule 13G/A - Stock Titan
Earnings call transcript: Grifols Q1 2026 sees mixed results with EPS beat - Investing.com
Grifols S.A. stock (ES0171996087): Leading player in plasma-derived medicines - AD HOC NEWS
Grifols S.A. stock (ES0171996087): Plasma therapy specialist faces pricing and regulatory headwinds - AD HOC NEWS
Earnings call transcript: Grifols Q1 2026 results show mixed signals, revenue miss - Investing.com
Grifols Q1 Earnings Call Highlights - Barchart
Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight - GlobeNewswire Inc.
Mittleman Value Partners 2025 Year-End & Q1 2026 Investment Review - Seeking Alpha
Grifols (NASDAQ: GRFS) 2025 revenue rises as leverage and risk factors stay elevated - Stock Titan
CapEx per share of Grifols, S.A. Sponsored ADR Class B – LSX:A1J1E2 - TradingView
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
Grifols S.A. stock (ES0171996087): Why does its plasma therapy model matter more for U.S. investors - AD HOC NEWS
Grifols, S.A. (GRFS) stock price, news, quote and history - Yahoo Finance UK
Grifols S.A. Stock: Navigating Debt Reduction Through US Biopharma IPO Plans Amid Market Pressures - AD HOC NEWS
Grifols S.A. stock surges as board approves potential US IPO for biopharma unit, unlocking value in - AD HOC NEWS
The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026 - FinancialContent
Grifols SA stock surges as board greenlights potential US IPO of plasma unit to slash debt and fuel - AD HOC NEWS
Grifols S.A. stock surges on board approval for potential US IPO of biopharma unit - AD HOC NEWS
Grifols: I'm Very Happy To Add In 2026 (NASDAQ:GRFS) - Seeking Alpha
Finanzdaten der Grifols Sa Adr-Aktie (GRFS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.33%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):